Supriya Lifescience Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

Supriya Lifescience announced that the U.S. Food and Drug Administration (US FDA) conducted an inspection at the Company's manufacturing facility located at Lote, Parshuram Industrial Area, Maharashtra, India, from 2 February 2026 to 6 February 2026.

The inspection concluded with the issuance of a Form 483 containing one (1) minor observation. The Company has adequately addressed the observation and has received the Establishment Inspection Report (EIR) indicating ?Voluntary Action Indicated (VAI)?, signifying a successful completion of the inspection.

The USFDA had conducted an inspection of the facility from 2 February 2026 to 6 February 2026. Following the inspection, the regulator issued a Form 483 with one minor observation and classifed the facility under voluntary action indicated status, which the company said has been adequately addressed.

The company said that it remains committed to maintaining full compliance with current Good Manufacturing Practice (cGMP) requirements across all its manufacturing facilities.

Supriya Lifesciences is primarily engaged in manufacturing of bulk drugs and pharmaceutical chemicals.The company?s primary focus is to build intermediaries and API for innovators and generic firms. It also exclusively collaborates with partners in the capacity of CMOs.

The company?s standalone net profit increased 6.18% to Rs 49.67 crore on 11.2% jump in revenue from operations to Rs 206.44 crore in Q4 FY26 over Q3 FY25.

Net profit of Supriya Lifescience rose 6.20% to Rs 49.68 crore in the quarter ended December 2025 as against Rs 46.78 crore during the previous quarter ended December 2024. Sales rose 11.20% to Rs 206.44 crore in the quarter ended December 2025 as against Rs 185.65 crore during the previous quarter ended December 2024.

Powered by Capital Market - Live News

Supriya Lifesciences will hold a meeting of the Board of Directors of the Company on 9 February 2026.

Powered by Capital Market - Live News